APSF 2026: Why Zero-Opioid Anesthesia Has ASCs at a Crossroads

The Protocol That Was Supposed to Fix Everything

For the better part of five years, the zero-opioid anesthesia movement swept through ambulatory surgery centers with the confidence of settled science. The logic was seductive: eliminate intraoperative opioids entirely, lean on regional blocks and multimodal adjuncts, and sidestep the well-documented harms of opioid-related adverse effects—nausea, respiratory depression, delayed discharge, and the downstream risk of persistent use. ERAS pathways in plastic surgery and outpatient settings embraced the framework enthusiastically. Administrators loved the optics. Metrics looked clean.

The problem is that the evidence never fully supported the rigidity with which the approach was applied. And now, in June 2026, the field's most authoritative patient safety body has said so explicitly.

The Anesthesia Patient Safety Foundation (APSF) published a formal position stating that "rigid adherence to zero-opioid targets may inadvertently compromise patient safety by prioritizing metric achievement over individualized care." That is not a nuanced hedge buried in a footnote—it is the organizing argument of a landmark June 2026 APSF article that every CRNA, anesthesiologist, and plastic surgeon working in an ASC should read before their next case.

The Scale of What's at Stake

Before dissecting the clinical argument, it's worth pausing on the scope of the problem. Ambulatory surgery is not a niche corner of American healthcare. According to the 2026 Anesthesiology Clinics preface on outpatient anesthesia, approximately 6,223 Medicare-certified ASCs were performing up to 70 million procedures per year as of 2023—with a projected trajectory exceeding 109 million procedures annually by 2033.

That volume means analgesic protocol decisions made at the ASC level are not merely clinical choices—they are population-health decisions. A flawed default applied at scale across tens of millions of cases compounds its errors proportionally. If a blanket zero-opioid protocol is poorly matched to even a fraction of those patients—the elderly patient with severe osteoarthritis undergoing bilateral hand surgery, the high-BMI patient with obstructive sleep apnea who paradoxically requires opioid titration to prevent hypoventilatory breakthrough pain, or the patient on buprenorphine for opioid use disorder whose mu-receptor dynamics defy standard dosing assumptions—the aggregate patient harm is substantial.

This is precisely why the APSF chose this moment to intervene.

What the Evidence Actually Shows (And What It Doesn't)

A July 2026 scoping review published in Cureus (Shukla et al.) analyzed 46 studies covering literature through May 2026 on opioid-free and opioid-sparing anesthesia strategies. The findings are instructive precisely because they resist the clean narrative that zero-opioid advocates have often promoted.

The review found that opioid-free and opioid-sparing strategies "may reduce perioperative opioid exposure and selected opioid-related adverse effects in appropriately selected procedures and patients"—but critically, the authors noted that "findings remain heterogeneous." That word, heterogeneous, is doing enormous clinical work. It means the benefit is real in some contexts and absent or reversed in others. It means patient selection, procedure type, surgical duration, and individual pharmacology all modulate outcomes in ways that a single protocol cannot anticipate.

The broader analgesic pharmacology literature reviewed in a 2026 PMC open-access review (Al-Awadhi et al.) confirms that non-opioid agents—NSAIDs, acetaminophen, NMDA antagonists like ketamine, IV lidocaine, gabapentinoids, alpha-2 agonists like dexmedetomidine, and regional anesthesia techniques—achieve "clinically meaningful opioid-sparing effects" comparable to opioid-based regimens in well-designed protocols. The same review, however, flags that "disproportionately high postoperative opioid prescribing in US settings underscores an urgent need for a paradigm shift toward multimodal, opioid-sparing strategies, consistent with global best practices."

Read those two sentences together. The problem is not that opioids should be avoided at all costs—it's that the US defaults to opioids as a first line rather than as one calibrated tool within a thoughtful multimodal framework. The solution is individualization, not inversion of the same binary thinking.

The Rebound Pain Problem: A Specifically ASC Vulnerability

For CRNAs and plastic surgeons operating in ambulatory settings, the APSF's June 2026 podcast companion to the position paper deserves particular attention. APSF Podcast Episode 313 flags a hazard that is simultaneously well-understood in regional anesthesia literature and routinely underweighted in ASC ERAS protocol design: single-shot regional block rebound pain.

The mechanism is straightforward. A brachial plexus block for an upper extremity procedure, an adductor canal block for knee arthroscopy, a pectoral nerve block for breast augmentation—these provide excellent intraoperative and early postoperative analgesia. But the block wears off. And when it does, 12 to 24 hours after placement, the patient experiences what the APSF describes as rebound pain that arrives "sometimes when the patient is already home."

This is the structural vulnerability of the zero-opioid ASC model. The ASC discharge metrics look exemplary—low pain scores at discharge, no PONV, no opioid administration charted. But the patient is now at home at 2 a.m. with an expired nerve block, no rescue opioid prescription (because the protocol is zero-opioid), and instructions that did not adequately prepare them for this transition. The result is not a protocol success. It is a patient safety failure that simply happened off-site and off the ASC's quality dashboard.

For plastic surgery specifically—where procedures like abdominoplasty, breast reconstruction with implants, brachioplasty, and liposuction carry meaningful inflammatory pain loads and are increasingly performed in office-based surgical suites and freestanding ASCs—this gap is acutely consequential. A patient who cannot reach adequate analgesia at home may self-medicate inappropriately, present to an emergency department, or simply endure unnecessary suffering that damages the surgical relationship and the practice's reputation.

What Individualized Multimodal Analgesia Actually Means in Practice

The APSF's core argument—that "patient safety is best supported by thoughtful, individualized clinical decision-making rather than rigid adherence to protocolized targets"—is not a license for inconsistency or a retreat from evidence-based care. It is an argument for precision over protocol.

In practical terms for an ASC CRNA or anesthesiologist, individualized multimodal analgesia means building an analgesic plan around patient-specific factors before the case begins:

• Opioid use history and current medications: A patient on buprenorphine/naloxone for opioid use disorder presents entirely different mu-receptor dynamics than an opioid-naive patient. The 2026 Anesthesiology Clinics includes a dedicated piece on managing patients on opioid use disorder medications in ambulatory surgery, a population that is growing in ASC settings and demands nuanced, individualized multimodal strategies—not a blanket zero-opioid default that may leave them profoundly undertreated.
• Procedure-specific pain trajectory: A 25-minute carpal tunnel release carries a fundamentally different postoperative pain arc than a 3-hour abdominoplasty with liposuction. The analgesic plan—including whether a short-acting opioid has a role intraoperatively or as a take-home rescue—should reflect that difference.
• Block duration planning: If a single-shot regional technique is used, the postdischarge analgesic bridge must be explicitly planned. That may mean scheduled acetaminophen (650–1000 mg every 6 hours), a scheduled NSAID (ibuprofen 600 mg every 8 hours with food, or celecoxib 200 mg twice daily in appropriate patients), and a clearly communicated expectation—documented in discharge instructions—that the block will resolve and pain will increase before it improves.
• Comorbidity screening: Renal impairment limits NSAID use. Hepatic compromise affects acetaminophen dosing. Chronic pain patients on gabapentinoids preoperatively may require dose continuation rather than de novo initiation. Sleep apnea severity may modulate how much opioid, if any, is appropriate at discharge.

None of this is conceptually novel. What is new is the formal APSF imprimatur signaling that the field has overcorrected—and that CRNAs and surgeons now have authoritative cover to push back against institutional zero-opioid mandates that were never nuanced enough to begin with.

The Documentation and Coordination Gap

Individualized multimodal analgesia is only as good as the communication infrastructure supporting it. A CRNA who makes a thoughtful, patient-specific intraoperative decision to administer 50 mcg of fentanyl for a patient whose block appears incomplete—a clinically appropriate choice—creates a downstream problem if that decision is not clearly communicated to the recovery nurse, the surgeon, and the discharge team. Similarly, a surgeon who prescribes a five-day course of oxycodone for a patient whose anesthesia provider already documented a robust multimodal plan with scheduled non-opioids is duplicating risk, not adding safety.

This coordination problem is where tools like VeriOp.ai become operationally relevant. Platforms designed to meet criteria for Clinical Decision Support under the 21st Century Cures Act can surface patient-specific analgesic risk signals during the preoperative workflow—flagging the buprenorphine patient, the renal-impaired patient for whom NSAIDs are contraindicated, or the chronic pain patient whose preoperative opioid tolerance suggests a conservative zero-opioid protocol will be inadequate—before the case reaches the OR. That kind of structured, preoperative decision support is what makes individualization scalable across a high-volume ASC rather than dependent on any single provider's recall.

The stakes are high enough to warrant that infrastructure. At 70 million ASC procedures per year and rising, analgesic decisions are not individual acts—they are system behaviors.

What This Means for ASC Administrators and Protocol Committees

For ASC medical directors and administrators who built zero-opioid ERAS pathways as quality benchmarks, the APSF's June 2026 position creates an important strategic and medicolegal consideration. A protocol that the field's leading patient safety foundation has formally identified as potentially compromising to patient safety is a protocol that deserves reexamination—regardless of how favorably it reads on a quality dashboard.

That reexamination does not mean abandoning opioid-sparing principles. The evidence from the Cureus scoping review and the PMC non-opioid analgesics review both affirm that reducing unnecessary opioid exposure is a legitimate and achievable goal. What it means is retiring the word zero in favor of a framework that is explicitly individualized, procedure-stratified, and patient-specific—and that treats the postdischarge analgesic period as part of the protocol, not an afterthought.

Protocol committees should consider reviewing current pathways against the following questions:

1. Does the current protocol have a documented decision pathway for patients on buprenorphine, methadone, or naltrexone?
2. Do discharge instructions explicitly address single-shot block resolution and provide a bridging analgesic strategy?
3. Are there procedure-specific analgesic tiers, or does a single pathway apply to a 20-minute laparoscopic procedure and a 3-hour body contouring case equally?
4. Is there a mechanism for the anesthesia provider to document and communicate intraoperative analgesic deviations from the standard pathway?

Platforms like VeriOp.ai—with preoperative screening workflows and a validation study supporting their clinical decision support function—are designed to help ASCs operationalize exactly this kind of structured, individualized analgesic risk stratification at the point of preoperative intake, not after the patient is already in the block room.

The Bottom Line for 2026

The zero-opioid anesthesia movement was a reasonable overcorrection to a genuine crisis of opioid overuse in perioperative care. But overcorrections, left unchallenged, become new orthodoxies—and new orthodoxies generate their own patient safety risks. The APSF has now formally named that risk. A robust scoping review has confirmed that the evidence base supports individualized opioid-sparing strategies, not blanket opioid elimination. And the scale of ambulatory surgery in the United States—tens of millions of procedures annually, approaching 109 million within a decade—means that getting this right is not an academic exercise.

For CRNAs, plastic surgeons, and ASC administrators, the path forward is clear even if it requires more cognitive work than a single-rule protocol: build analgesic plans around the patient in front of you, plan explicitly for the postdischarge period when blocks wear off and patients are at home, and use the full pharmacopeia—NSAIDs, acetaminophen, ketamine, dexmedetomidine, IV lidocaine, gabapentinoids, regional techniques, and yes, judicious opioids when clinically indicated—as tools rather than ideological positions.

The APSF is not telling clinicians to return to the days of fentanyl-heavy anesthesia. It is asking the field to stop confusing metric performance with patient safety. In 2026, those are not the same thing.